Short answer
Surgery Partners, Inc. (SGRY) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $815M (down 0.8% year over year) with net income of −$21M.
Q3 2026 key financials · XBRL
- Revenue
- $815M
- −0.8% YoY · −4.0% QoQ
- Net income
- −$21M
- +7.0% YoY · −40.7% QoQ
- Operating margin
- 10.5%
- EPS (diluted)
- −$0.16
- +11.1% YoY · −33.3% QoQ
Source: XBRL data from the Surgery Partners, Inc. (SGRY) Q3 2026 10-Q on SEC EDGAR. USD.
Surgery Partners, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $815.3M, down 0.8% YoY from $821.5M, despite same-facility revenue growth of 6.0%
- Cost margin 77.3% vs 76.2% YoY, operating margin 10.5% vs 12.9%, net loss $21.1M vs $22.7M
- Best performance: same-facility revenue per case up 5.8%; worst: other service revenue $17.3M vs $23.0M
- Cash $354.5M vs $239.9M at December 31, 2025; operating cash flow $174.5M, up from $170.9M
- $285.0M Term Loan prepayment; outlook supported by operating cash flow, cash and $692.8M Revolver capacity, with inflation and supply-chain risks remaining headwinds
Risk Factors
- Merger completion risk, triggered by October 23 agreement and November 8 amendment, with HSR clearance and stockholder approval required
- Termination exposure: approximately $149.1 million fee plus expense reimbursement capped at $8.25 million
- Regulatory risk: Hart-Scott-Rodino waiting-period termination or injunction could prevent closing
- Operational risk: merger uncertainty may cause key personnel departures and impair execution
- Litigation risk: securities or derivative lawsuits could delay closing and reduce liquidity
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Surgery Partners, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.